NASDAQ:LOGC - LogicBio Therapeutics Stock Price, News, & Analysis

$13.46
+0.50 (+3.86 %)
(As of 07/17/2019 04:00 PM ET)
Today's Range
$13.00
Now: $13.46
$13.67
50-Day Range
$11.10
MA: $13.37
$17.90
52-Week Range
$6.70
Now: $13.46
$20.07
Volume28,970 shs
Average Volume21,653 shs
Market Capitalization$302.72 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
LogicBio Therapeutics, Inc., a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect. Its lead product candidate is LB-001 for the treatment of Methylmalonic Acidemia, a life-threatening disease that presents at birth. The company has a partnership with Children's Medical Research Institute to develop new viral vectors. LogicBio Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:LOGC
CUSIPN/A
CIKN/A
Phone617-245-0399

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$3.62 per share

Profitability

Miscellaneous

Employees23
Market Cap$302.72 million
Next Earnings Date8/13/2019 (Estimated)
OptionableNot Optionable

Receive LOGC News and Ratings via Email

Sign-up to receive the latest news and ratings for LOGC and its competitors with MarketBeat's FREE daily newsletter.

LogicBio Therapeutics (NASDAQ:LOGC) Frequently Asked Questions

What is LogicBio Therapeutics' stock symbol?

LogicBio Therapeutics trades on the NASDAQ under the ticker symbol "LOGC."

How were LogicBio Therapeutics' earnings last quarter?

LogicBio Therapeutics Inc (NASDAQ:LOGC) issued its quarterly earnings results on Tuesday, May, 14th. The company reported ($0.34) earnings per share for the quarter, missing analysts' consensus estimates of ($0.32) by $0.02. View LogicBio Therapeutics' Earnings History.

When is LogicBio Therapeutics' next earnings date?

LogicBio Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, August 13th 2019. View Earnings Estimates for LogicBio Therapeutics.

What price target have analysts set for LOGC?

4 brokerages have issued twelve-month target prices for LogicBio Therapeutics' shares. Their predictions range from $20.00 to $26.00. On average, they expect LogicBio Therapeutics' stock price to reach $24.00 in the next twelve months. This suggests a possible upside of 78.3% from the stock's current price. View Analyst Price Targets for LogicBio Therapeutics.

What is the consensus analysts' recommendation for LogicBio Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for LogicBio Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for LogicBio Therapeutics.

What are Wall Street analysts saying about LogicBio Therapeutics stock?

Here are some recent quotes from research analysts about LogicBio Therapeutics stock:
  • 1. According to Zacks Investment Research, "LogicBio Therapeutics Inc. is a genome editing company. It focuses on developing medicines to treat rare diseases in patients with significant unmet medical needs. The company's technology platform consists of GeneRide(TM). LogicBio Therapeutics Inc. is based in Cambridge, Massachusetts. " (4/10/2019)
  • 2. Chardan Capital analysts commented, "We initiate coverage of Buy rating (PT $20) on the potential of LogicBio’s GeneRide in vivo genome editing (GE) to address severe pediatric genetic diseases. LogicBio’s pipeline is based on its nuclease-free, promoterless GeneRide technology, which inserts AAV-delivered therapeutic transgenes into precise locations in the genome via homologous recombination. The company’s lead asset, LB-001, is a liver-directed GE therapeutic for methylmalonic acidemia (MMA), an inherited metabolic disorder that presents in infancy and carries a high risk of death. Liver transplantation has been shown to improve outcomes, supporting the use of liver-directed genetic medicines (GMs)." (11/13/2018)

Has LogicBio Therapeutics been receiving favorable news coverage?

News stories about LOGC stock have trended somewhat negative this week, InfoTrie reports. The research firm ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. LogicBio Therapeutics earned a daily sentiment score of -1.5 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for LogicBio Therapeutics.

Are investors shorting LogicBio Therapeutics?

LogicBio Therapeutics saw a increase in short interest in the month of June. As of June 30th, there was short interest totalling 110,400 shares, an increase of 25.3% from the May 30th total of 88,100 shares. Based on an average daily volume of 27,600 shares, the short-interest ratio is currently 4.0 days. Currently, 0.9% of the shares of the stock are sold short. View LogicBio Therapeutics' Current Options Chain.

Who are some of LogicBio Therapeutics' key competitors?

What other stocks do shareholders of LogicBio Therapeutics own?

Who are LogicBio Therapeutics' key executives?

LogicBio Therapeutics' management team includes the folowing people:
  • Mr. Frederic Chereau, Pres, CEO & Director (Age 52)
  • Mr. Matthias B. Jaffé, Chief Financial Officer (Age 50)
  • Mr. Tom Wilton, Chief Bus. Officer (Age 45)
  • Dr. Leszek Lisowski Ph.D., Co-Founder
  • Dr. Adi Barzel, Co-Founder

When did LogicBio Therapeutics IPO?

(LOGC) raised $77 million in an initial public offering (IPO) on Friday, October 19th 2018. The company issued 5,800,000 shares at $12.50-$14.00 per share. Jefferies, Barclays and William Blair acted as the underwriters for the IPO and Chardan was co-manager.

How do I buy shares of LogicBio Therapeutics?

Shares of LOGC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is LogicBio Therapeutics' stock price today?

One share of LOGC stock can currently be purchased for approximately $13.46.

How big of a company is LogicBio Therapeutics?

LogicBio Therapeutics has a market capitalization of $302.72 million. The company earns $-17,620,000.00 in net income (profit) each year or ($3.04) on an earnings per share basis. LogicBio Therapeutics employs 23 workers across the globe.View Additional Information About LogicBio Therapeutics.

What is LogicBio Therapeutics' official website?

The official website for LogicBio Therapeutics is http://www.logicbio.com/.

How can I contact LogicBio Therapeutics?

LogicBio Therapeutics' mailing address is 99 ERIE STREET, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-245-0399 or via email at [email protected]


MarketBeat Community Rating for LogicBio Therapeutics (NASDAQ LOGC)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  39 (Vote Outperform)
Underperform Votes:  49 (Vote Underperform)
Total Votes:  88
MarketBeat's community ratings are surveys of what our community members think about LogicBio Therapeutics and other stocks. Vote "Outperform" if you believe LOGC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LOGC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/17/2019 by MarketBeat.com Staff

Featured Article: Accumulation/Distribution

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel